SCHEMBL5744073

SCHEMBL5744073

COc1cc(C=NCC(OC)OC)ccc1OCc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.60
HPGD P15428 5/20 0.60
HTT P42858 2/20 0.60
SMN1; SMN2 Q16637 5/20 0.56
MAPT P10636 3/20 0.56
GAA P10253 1/20 0.56
NPC1 O15118 3/20 0.54
RAB9A P51151 3/20 0.54
GFER P55789 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
AMY1A P0DUB6 1/20 0.54
KMT2A Q03164 4/20 0.52
MEN1 O00255 3/20 0.52
POLB P06746 2/20 0.52
NFKB1 P19838 1/20 0.52
NFKB2 Q00653 1/20 0.52
RELA Q04206 1/20 0.52
TP53 P04637 1/20 0.52
PAX8 Q06710 1/20 0.52
KLF5 Q13887 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5744070 1.00 ALDH1A1 (0.60) ALDH1A1HPGDHTTSMN1; SMN2MAPT
SCHEMBL5745493 0.95 AMY1A (0.60) ALDH1A1HPGDHTTSMN1; SMN2MAPT
SCHEMBL5745496 0.95 AMY1A (0.60) ALDH1A1HPGDHTTSMN1; SMN2MAPT
SCHEMBL16764895 0.91 ALDH1A1 (0.57) ALDH1A1HPGDHTTSMN1; SMN2MAPT
SCHEMBL16764892 0.91 ALDH1A1 (0.57) ALDH1A1HPGDHTTSMN1; SMN2MAPT
SCHEMBL16764095 0.87 AMY1A (0.56) ALDH1A1HPGDHTTSMN1; SMN2MAPT
SCHEMBL16764093 0.87 AMY1A (0.56) ALDH1A1HPGDHTTSMN1; SMN2MAPT
SCHEMBL2233181 0.84 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2MAPTGAANPC1
SCHEMBL2233185 0.84 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2MAPTGAANPC1
SCHEMBL12348660 0.84 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2MAPTGAANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067529-B2 Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors HOFFMANN-LA ROCHE INC. (US) 2006-06-27 US disclosed
EP-1631551-A2 ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2006-03-08 EP disclosed
US-20040259910-A1 Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors BOLIN DAVID ROBERT (US) 2004-12-23 US disclosed
WO-2004101528-A2 ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2004-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259910-A1 Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors GFPT1, GLS2, GLS ALDH1A1 1211/4885HPGD 892/4885HTT 1885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.